Infection biology and antibiotic resistance in a united perspective: from epidemiology to new antibacterial treatment strategies

Project funded by The Research Council of Norway.

New antibacterial strategies are an urgent necessity due to increasing antibiotic resistance and infection treatment problems.

Examples of new strategies include antiviral, collateral sensitivity (how a specific antibiotic weakens the bacterial ability to resist other classes of antibiotics), new antimicrobial molecules, colonization resistance, inhibition of resistance proliferation and enhancement of host immune system.

iResist consists of an interdisciplinary group of Norwegian research groups and researchers from several fields, who will work together to position themselves and develop EU applications.
A solid expertise in host microbe interactions, antibiotic resistance, molecular biology, genomics & system biology, evolution, clinical microbiology, cell biology, veterinary & human medicine, pharmacology, immunology and epidemiology is crucial to identify new treatment strategies.

Members of the iResist Consortium:

• UiT, The Arctic University of Norway, Tromsø leads the iResist project.
• UiO, University of Oslo
• NMBU, Norwegian University of Life Sciences
• OSLO MET, Oslo metropolitan University (previously HiOA)
• UNN, University Hospital of North Norway
• Norwegian Veterinary Institute
• Stavanger University Hospital